Previous 10 | Next 10 |
ClearBridge is a leading global asset manager committed to active management. Research-based stock selection guides our investment approach, with our strategies reflecting the highest-conviction ideas of our portfolio managers. Higher yields as well as uncertainty over inflation, supp...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the third quarter 2021 after market close on Thursday, November 4, 2021. Company management will be webcasting a corresponding conference call beginning at 1:30...
1,000-patient prospective study in 11 solid tumors will monitor ctDNA levels up to five years Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, has initiated the Observation of ResiduAl Cancer with Liquid biopsy Evaluation (ORACLE) study, a 1,000-pati...
Shares of healthcare company Guardant Health (NASDAQ: GH) are down 14.2% as of mid-session today on the heels of unconfirmed reports that it's interested in acquiring peer and indirect rival NeoGenomics (NASDAQ: NEO) . Only citing "people familiar with the matter," Bloom...
Most people want to be financially secure in retirement. To achieve that goal, many shrewdly turn to the stock market. Investing in stocks allows your money to grow substantially more than, say, in a traditional savings account. Of course, the stock market also comes with risks, but picking...
Halvorsen's 13F portfolio value decreased marginally from $33.58B to $32.98B this quarter. The number of positions decreased from 94 to 88. Viking Global added FIGS Inc. & JD.com and increased Amazon.com & General Electric during the quarter. The top three positions are Am...
Guardant Health, Inc. (Nasdaq: GH), along with leading academic institutions and pharmaceutical companies, share data highlighting molecular targets of importance, treatment resistance patterns, and advantages of using the Guardant360 ® liquid biopsy test to help improve the manage...
GuardantINFORM™ clinical-genomic liquid biopsy dataset underscores need to improve HER-2 directed treatment in metastatic colorectal cancer Guardant Health, Inc. (Nasdaq: GH), along with leading academic institutions and pharmaceutical companies, share data highlighti...
REDWOOD CITY, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) -- Guardant Health, Inc. (Nasdaq: GH) along with leading academic institutions and pharmaceutical companies will present data demonstrating the advantages of using the Guardant360 ® liquid biopsy test for clinical decision-makin...
The precipitous cost decline of next-generation DNA sequencing has supercharged our understanding of tumor biology. The strange biology that makes it dangerous also gives scientists the opportunity to detect cancer earlier. The exponential cost declines associated with NGS, AI, an...
News, Short Squeeze, Breakout and More Instantly...
Shield is first blood test approved by FDA as a primary screening option for colorectal cancer and that meets performance requirements for Medicare coverage Blood test offers easy, convenient and pleasant screening option with potential for improving colorectal cancer screening rates ...
Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the second quarter 2024 after market close on Wednesday, August 7, 2024. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Ti...
Running on Guardant Infinity™ smart liquid biopsy platform, new Guardant360 test covers over 10 times more genes, including all guideline-recommended genomic biomarkers across advanced solid tumors, and quantifies tumor burden with 10 times higher sensitivity Upgraded test covered ...